Compare KELYA & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KELYA | LXEO |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | 4900 | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.1M | 369.8M |
| IPO Year | N/A | 2023 |
| Metric | KELYA | LXEO |
|---|---|---|
| Price | $11.94 | $4.50 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | $15.00 | ★ $18.44 |
| AVG Volume (30 Days) | 475.6K | ★ 631.3K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.98 | $3.60 |
| 52 Week High | $14.94 | $10.99 |
| Indicator | KELYA | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 68.86 | 42.22 |
| Support Level | $8.30 | $4.44 |
| Resistance Level | $12.01 | $7.90 |
| Average True Range (ATR) | 0.44 | 0.30 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 84.21 | 39.29 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.